Episodes 136-150 of 260
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
The Clinical Use of HER2-Targeted Therapies in Gastric Cancer: The Current and Emerging Landscape
CME/CEThe Clinical Use of HER2-Targeted Therapies in Gastric Cancer: The Current and Emerging Landscape
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
CME/CEMastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
CME/CENoncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
CME/CECommunity Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CEWarm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
CME/CETargeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?